Theratechnologies' NDA for Tesamorelin to be Reviewed by an FDA Advisory Committee

November 5, 2009 – Theratechnologies today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (“FDA”) will review Theratechnologies’ NDA for tesamorelin in the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy.

the details can be read here.